Media Advisory

 

OCT 29 - NOV 1:

GLOBAL EXPERTS TO SHARE LATEST ADVANCEMENTS IN ALZHEIMER’S RESEARCH

 

17th Annual Clinical Trials on Alzheimer's Disease International Conference Happening in Madrid, Spain and Virtually
 

WHAT: The 17th annual Clinical Trials on Alzheimer's Disease (CTAD) international conference brings together 2,200 leading experts in Madrid and online to discuss the latest therapeutic advances in Alzheimer’s disease. Scientists from across the globe will present clinical trial results and new therapeutic strategies to treat people experiencing all stages of the disease, including the latest in prevention of Alzheimer’s.

 

Key presentations for 2024 include a review of a novel screening process used in the AHEAD Study; testing lecanemab on individuals without noticeable symptoms; donanemab use recommendations and preclinical results from the TRAILBLAZER-ALZ 3 study; and Phase II insights from the TOGETHER trial evaluating the efficacy, safety and tolerability of bepranemab in early-stage Alzheimer’s disease.

 

Several sessions will highlight the latest findings related to performance of plasma p-tau217, including a roundtable discussion on current uses and future considerations for diagnostic and clinical practice.   

 

This year's convening also includes sessions on interim results from Phase I and Phase II drug development trials, as well as emerging therapies, measurement of speech patterns to evaluate memory loss, the potential effects of social determinants of health on amyloid levels, and more.

 

All sessions will be livestreamed and recorded for conference registrants.

 

View the conference program here.

 

WHEN:
Tuesday, Oct. 29 – Friday, Nov. 1

 

WHERE:
Madrid Marriott Auditorium Hotel and Conference Center, Madrid, Spain; and the CTAD virtual platform

 

RSVP:

To request a press pass, please email CTAD media liaison Jameson Roth by Monday, Oct. 21 at JRoth@MessagePartnersPR.com or 443-717-3508.

 

All research is embargoed until the date/time that it is available on-demand or shared at a CTAD live presentation. Media may receive embargoed abstracts before the conference by emailing Jameson Roth at JRoth@MessagePartnersPR.com, agreeing in writing to CTAD's embargo policy. 

 

# # #

 

About CTAD

Since 2008, CTAD has been a conference organized and planned by Alzheimer's disease (AD) clinical researchers for AD clinical researchers. CTAD embraces the organizing committee mandate to maintain CTAD's unique role in AD research: To provide a substantive, clinical research-oriented conference and an annual opportunity for the world's preeminent clinical researchers to engage in both formal and informal exchanges of views. CTAD's ongoing commitment to providing a relatively intimate forum has resulted in the conference's reputation of facilitating and fostering international collaboration in AD clinical research matters. More information is available at http://www.ctad-alzheimer.com/.